Navigation Links
Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Date:6/3/2008

percent; no patient achieved an objective response. The median PFS was 2.3 months. Three patients had a >6 month PFS. The disease control and median PFS are similar to results achieved in this patient population for approved agents (panitumumab or cetuximab monotherapy).

Safety data were qualitatively similar to that of irinotecan and a fluoropyrimidine with neutropenia, diarrhea, nausea, vomiting and fluid loss events (dehydration and hypokalemia) being the most common. The 210 unit/m2 dose produced more toxicities than seen in the CPX-1 Phase 1 clinical trial, resulting in only 40 percent of patients receiving >80 percent of the planned dose intensity. Treatment will be initiated at a lower dose in future studies.

"The efficacy results in this study are very encouraging, particularly compared to historical data," said Arthur Louie, M.D., chief medical officer of Celator. "These data support that drug ratios may play an important role when combining drugs to treat patients. This study shows that well established drugs with proven activity may offer greater clinical benefit when a synergistic ratio is identified and the individual drugs are locked into a drug delivery vehicle able to deliver and maintain the desired ratio in patients. Our goal is to substantially improve clinical outcomes by using our proprietary CombiPlex(TM) technology."

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach that identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle and maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorect
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
2. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
5. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
10. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
11. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 The Parenteral Drug Association ... global post-approval changes protocols. The new ... topic expressed by industry participants and regulatory authority representatives ... month in Washington, DC . Representatives ... hand for the workshop. Attendees indicated openness to engaging ...
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
(Date:9/19/2014)... 2014  The board of directors of AbbVie Inc. ... dividend of $0.42 per share.  The ... of record at the close of business on Oct. ... global, research-based biopharmaceutical company formed in 2013 following separation ... expertise, dedicated people and unique approach to innovation to ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... Calif., Sept. 24 Amgen (Nasdaq: AMGN ... PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from ... precaution.  The product that is being recalled may contain ... in most cases. The lamellae result from the interaction ...
... BIOD ) announced today that it will be presenting at the ... Conference, September 28, 2010 at 12:00 pm Eastern time at the ... access a link to the live webcast of the presentation from ... . Replays of the presentation will be available for 90 days. ...
Cached Medicine Technology:Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 2Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 3Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 4Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 5Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 6Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 7Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 8Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 9Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 10Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 11Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 12Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 13Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 14Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 15Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 16Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 17Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 18Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 19Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 20Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 21
(Date:9/20/2014)... 2014 "As a nurse, patients always ask ... an inventor from Tamaqua, Pa. "The reason that they cannot ... of their chairs. My invention enables them to check oxygen ... Sensor to make it easier to monitor the contents of ... when the tank is low. It allows changeovers to be ...
(Date:9/20/2014)... Angeles, CA (PRWEB) September 20, 2014 ... score of 3.1 out of 5, indicating a moderately ... firm IBISWorld, this score reflects current and future pricing ... from historically high prices. Other factors that negatively affect ... in demand for construction and the moderate switching costs. ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... 20, 2014 Final Cut Pro X ... release of the Information theme for FCPX filmmakers. , “Fun, ... describe the Information theme,” says Christina Austin, CEO of Pixel ... so professional.” , Information features easy to use controls that ... the environment. Change the background color, color of each circle ...
(Date:9/20/2014)... The first federal bellwether trial of a DePuy ... in the U.S. District Court, Northern District of Texas, ... the week opened in the DePuy Pinnacle Hip ... vice president, who discussed the clinical testing performed on ... According to Reuters, the executive stated that the Pinnacle ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4
... disease ... ATLANTA, Nov. 12 One year following the launch of,operations ... Care,Improvement Plus feel their health has maintained or improved, according ... regional,membership. Of those who feel health has improved, 97 percent ...
... give patients a new lease on life. , ... ... back pain are reaching out to an innovative solution helping them ... With facilities in Tampa and Scottsdale, the Laser Spine Institute is ...
... official,breaking news service for North American companies participating in MEDICA,2008, ... The profile of Hokanson follows below., ... 9 /C 02 Web URL : ... the early 1970,s to provide the,instruments for Dr. Eugene Strandness, ...
... Technologies, IntelliFill i.v. robot to ... reduces errors and hospital ... Technologies,Inc., a pioneer in medication error reduction and hospital ... robotic I.V. dose,preparation system, IntelliFill i.v.(TM), by the Alegent ...
... survey shows health improvements, disease ... of plan -, SAN ANTONIO, Nov. 12 One ... members of Care Improvement Plus feel,their health has maintained or ... plan,s statewide membership. Of those who,feel health has improved, 97 ...
... Bioef are taking part in a European project the goal ... revolutionise the manner of controlling flu epidemics internationally, thanks to ... from the current 24 hours to a period of between ... number of control points. This research, in which other European ...
Cached Medicine News:Health News:Georgia and South Carolina Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Laser Spine Institute Helping Patients to "Stand Up and Be Free" from Debilitating Back Pain 2Health News:Laser Spine Institute Helping Patients to "Stand Up and Be Free" from Debilitating Back Pain 3Health News:Hokanson Exhibiting at MEDICA 2008 2Health News:Alegent Health System Automates I.V. Preparation to Enhance Patient Safety 2Health News:Texas Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Design of system that will revolutionize control of influenza epidemics 2
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The SB Charit is a prosthesis system consisting of two endplates made of high quality cobalt chromium alloy with an ultra high molecular weight polyethylene sliding core placed between them....
... The D185 is ... FDA clearance for this ... transcranial motor evoked potentials ... surgical procedures such as ...
Medicine Products: